Pierre Fabre Laboratories Receives the Galien International Prize for EBVALLO, the First Allogeneic Immunotherapy for Patients With a Rare Cancer
Pierre Fabre Laboratories Receives the Galien International Prize for EBVALLO, the First Allogeneic Immunotherapy for Patients With a Rare Cancer
CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO (tabelecleucel), indicated as monotherapy for the treatment of patients with post-transplant lymphoproliferative disorder positive for Epstein-Barr virus (EBV+ PTLD) who have received at least one prior treatment.
Pierre Fabre实验室以EBVALLO (tabelecleucel)在单剂量疗法下用于治疗表达为Epstein-Barr病毒(EBV+ PTLD)阳性的移植后淋巴增生性疾病患者(PTLD)至少已接受一种前期治疗的药品，获得了“Prix Galien International”最佳罕见/孤儿疾病类别产品奖。
During the same ceremony, EBVALLO received the "Prix Galien" Italy Award in the Advanced Therapy Medicinal Product category. These two exceptional recognitions follow the awarding of EBVALLO for the "Prix Galien France" on December 2023
在同一颁奖典礼上，EBVALLO荣获“Prix Galien”意大利先进疗法药品类别奖项。这两个卓越奖项的颁发紧随EBVALLO于2023年12月获得“Prix Galien France”奖项。
As a symbol of scientific rigor, excellence, and innovation, the "Prix Galien International" awards remarkable recent health innovations available to the public, following an evaluation done by an independent committee of experts. Today this prize exists in fifteen countries, its reputation and influence have made it the most prestigious distinction in the medical field. Through this prize, the jury honors EBVALLO, thanks to its innovative manufacturing process and mechanism of action. It offers rapid and lasting clinical results in over 50% of cases, in a rare disease with a particularly unfavorable prognosis, leading to significant morbidity and mortality.
作为科学严谨、卓越和创新的象征，“Prix Galien International”向公众提供了杰出的新近健康创新，经过独立专家委员会的评估后获得了这个奖项。如今，这个奖项在十五个国家都有，它的声誉和影响使其成为医学领域最负盛名的荣誉。通过这个奖项，评审委员会赞赏EBVALLO的创新制造工艺和作用机制。它在一种预后极劣的罕见病中，在超过50%的病例中提供了快速和持久的临床结果，导致重大的发病率和死亡率。
This award highlights the innovation capacity of Pierre Fabre Laboratories in oncology, one of its priority areas of development, and its ability to establish successful collaborations, such as the one with Atara Biotherapeutics (ATARA), an American biotech company. A global agreement was signed in December 2023, providing Pierre Fabre Laboratories with the EBVALLO development, manufacturing, and commercialization rights all over the world. EBVALLO was approved by the European Medicines Agency (EMA) in December 2022, and to date, this promising new treatment is marketed in Germany and Austria. In Europe, EBVALLO is available to patients as part of an Early Access Program since July 2023.
此次奖项突出了Pierre Fabre实验室在肿瘤学领域的创新能力，也是其发展优先领域之一，而且它具备建立成功合作关系的能力，例如与美国生物技术公司Atara Biotherapeutics (ATARA)的合作。于2023年12月签署了一项全球协议，为Pierre Fabre实验室提供了EBVALLO在全球范围内的开发、制造和商业化权利。EBVALLO于2022年12月获得欧洲药品管理局(EMA)批准，在德国和奥地利上市销售。在欧洲，自2023年7月以来，EBVALLO作为早期接触计划的一部分，已经对患者开放。
"We are very proud to receive this award, which we dedicate to the patients. It is a recognition of the major therapeutic advancement that EBVALLO represents for patients with a rare cancer and a very unfavorable prognosis, who until now had significant unmet needs. This cancer, which affects a few hundred people worldwide each year, resonates perfectly with our purpose: every time we take care for a single person, we make the whole world better." said Éric Ducournau, CEO of the Pierre Fabre Laboratories.
“我们非常自豪地获得了这个奖项，我们把它献给患者。这是对EBVALLO在少数癌症患者中所代表的重大治疗进展的认可，这些患者预后极差，直到现在仍需求助于之前无法满足的需求。这种癌症每年在全球只影响到少数几百人，它与我们的宗旨完美契合：每当我们为一个人提供护理时，我们都让整个世界变得更好。”Pierre Fabre实验室CEO Éric Ducournau 表示:“我们非常自豪地获得了这个奖项，我们把它献给患者。”
CONTACT: Laurence MARCHAL, [email protected]
联系人：Laurence MARCHAL，[email protected]
PDF-
Photo -
Logo -
PDF-
照片-
标志 -
SOURCE Pierre Fabre
来源Pierre Fabre